Deals
Sanofi Is Said to Mull Options for $30 Billion Consumer Arm
- Drugmaker gauges investor feedback on options to extract value
- CEO Hudson scheduled to give strategy update at Dec. 10 event
This article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
Sanofi is holding discussions over options for its consumer-health business that could be worth $30 billion as new Chief Executive Officer Paul Hudson seeks to rejuvenate the French drugmaker, people familiar with the matter said.